Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 M4PJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP1UZhKSzVyPUCuNFAxOjh5IN88US=> MUjTRW5ITVJ?
LC-2-ad NUDD[GllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zJVGlEPTB;MD6wNFA{OTdizszN MmfFV2FPT0WU
RL95-2 NFzUcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMECwOlY5KM7:TR?= NGjUTmxUSU6JRWK=
MZ1-PC MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrSPWh3UUN3ME2wMlAxODd{OTFOwG0> NXXrPIpZW0GQR1XS
TE-8 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SzfWlEPTB;MD6wNFEyPyEQvF2= NVjvSGFoW0GQR1XS
SW954 NEW4UFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLBTWM2OD1yLkCwNVE6KM7:TR?= MkHHV2FPT0WU
TE-11 NHq1PVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMECxNlMh|ryP MX7TRW5ITVJ?
PSN1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX0XoxxUUN3ME2wMlAxOTNizszN NFXmdJJUSU6JRWK=
MOLT-4 M{DTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HFbGlEPTB;MD6wNFE1QSEQvF2= NU\QUIh5W0GQR1XS
697 M1[wfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqxd|I{UUN3ME2wMlAxOTVizszN NXe5NGF5W0GQR1XS
ETK-1 M4[1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fHUWlEPTB;MD6wNFE2OiEQvF2= Mn\zV2FPT0WU
TE-10 NVX5WG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrwOFRKSzVyPUCuNFAyPTRizszN NHr0UVlUSU6JRWK=
HUTU-80 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFex[5JKSzVyPUCuNFAyPjhizszN MXTTRW5ITVJ?
NTERA-S-cl-D1 M{HHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjtZ2pKSzVyPUCuNFAzODlizszN MWXTRW5ITVJ?
MFH-ino NWH4UGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PXW2lEPTB;MD6wNFI3QCEQvF2= Mly1V2FPT0WU
IA-LM Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPZcVFRUUN3ME2wMlAxOjhizszN NWe4XHFuW0GQR1XS
MC116 NWX0OIhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMECyPFkh|ryP M{T3c3NCVkeHUh?=
RKO M2rUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMECyPVgh|ryP MlXYV2FPT0WU
MRK-nu-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIriUZFKSzVyPUCuNFAzQTlizszN NHixS3FUSU6JRWK=
VA-ES-BJ MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO4OZpGUUN3ME2wMlAxOyEQvF2= MkH2V2FPT0WU
KALS-1 M4HF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV75ZWhzUUN3ME2wMlAxOzB6IN88US=> NVryeJl[W0GQR1XS
BB30-HNC NWftOXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj0fml6UUN3ME2wMlAxOzF2IN88US=> MmPRV2FPT0WU
ACN M2rR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfaXXZKSzVyPUCuNFA{OTZizszN NHjDUoJUSU6JRWK=
TE-9 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImxUmFKSzVyPUCuNFA{OjZizszN NIrT[HZUSU6JRWK=
SIG-M5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnRfoZKSzVyPUCuNFA{OjdizszN M3n2RXNCVkeHUh?=
no-10 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG3VVNKSzVyPUCuNFA{PjJizszN M3PROnNCVkeHUh?=
EW-1 NX3SN|dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7QZoozUUN3ME2wMlAxOzdzIN88US=> M4qxenNCVkeHUh?=
SK-LMS-1 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xtc2lEPTB;MD6wNFQxOSEQvF2= M2DXOXNCVkeHUh?=
GT3TKB NWrqZXdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzHVHhyUUN3ME2wMlAxPDN2IN88US=> M2fCTHNCVkeHUh?=
ES4 NYX0PHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TTfmlEPTB;MD6wNFQ1QSEQvF2= Mkn6V2FPT0WU
IMR-5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF21XphKSzVyPUCuNFA1PSEQvF2= NFjRRYZUSU6JRWK=
NCI-H1648 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD1yLkCwOFY6KM7:TR?= NHLwfJBUSU6JRWK=
MV-4-11 M2r1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K1VmlEPTB;MD6wNFQ4PSEQvF2= NXq4RZFEW0GQR1XS
SK-UT-1 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u4dGlEPTB;MD6wNFQ5KM7:TR?= NWXsPXBrW0GQR1XS
NB13 M{fJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fY[2lEPTB;MD6wNFQ6OSEQvF2= MoLrV2FPT0WU
DJM-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vY[GlEPTB;MD6wNFU{KM7:TR?= NVzVNm9OW0GQR1XS
ES8 NYPn[nIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HOVWlEPTB;MD6wNFU{QCEQvF2= NG\CSVFUSU6JRWK=
TE-6 M37FcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEC1O{DPxE1? NXjScmFtW0GQR1XS
KS-1 NIS2ZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEC1PFIh|ryP NEHOdoxUSU6JRWK=
TE-1 NX;wUWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvsd25jUUN3ME2wMlAxPjB4IN88US=> NHP4Um9USU6JRWK=
ATN-1 M3nocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLkTWM2OD1yLkCwOlA6KM7:TR?= NEnHWpFUSU6JRWK=
A4-Fuk M{nROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTrTWM2OD1yLkCwOlEyKM7:TR?= NInReYlUSU6JRWK=
ALL-PO NUn2W5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEC2N{DPxE1? M{j0THNCVkeHUh?=
BE-13 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjuN4FkUUN3ME2wMlAxPjN4IN88US=> NUDVZ4djW0GQR1XS
KM12 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEC2N|ch|ryP MlzhV2FPT0WU
NOS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfSTWM2OD1yLkCwOlUh|ryP MmiyV2FPT0WU
SW962 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLTTWM2OD1yLkCwOlYzKM7:TR?= NYHFWmVoW0GQR1XS
OCUB-M M{DXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLLbVhKSzVyPUCuNFA3PjJizszN MlLSV2FPT0WU
NCI-H510A MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEC2OlUh|ryP NVn1b2FRW0GQR1XS
EW-16 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED6V4tKSzVyPUCuNFA3QTRizszN NVPwbXFPW0GQR1XS
KGN M1vtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLMTWM2OD1yLkCwO|EzKM7:TR?= MkjrV2FPT0WU
LS-411N M{LqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq1TWM2OD1yLkCwO|E4KM7:TR?= M4H3WHNCVkeHUh?=
Becker MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3vTWM2OD1yLkCwO|Ih|ryP NH\6V|NUSU6JRWK=
HC-1 M{fEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDQR4xKSzVyPUCuNFA4OjFizszN MW\TRW5ITVJ?
CESS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPO[oVKSzVyPUCuNFA4OzdizszN MVrTRW5ITVJ?
KURAMOCHI MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrhdVlKSzVyPUCuNFA4PDhizszN NGSyUGRUSU6JRWK=
TGBC24TKB M{PZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13u[mlEPTB;MD6wNFc2OiEQvF2= Moi2V2FPT0WU
SW982 NWCzUJQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEC3OlYh|ryP NXu0XVQ4W0GQR1XS
HCE-4 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEC3Olch|ryP NFTUbVNUSU6JRWK=
LOUCY NYDEVIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHxe2l3UUN3ME2wMlAxPzd3IN88US=> MV7TRW5ITVJ?
8-MG-BA MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnkTodKSzVyPUCuNFA4QTZizszN NHXKW|dUSU6JRWK=
HT-144 NUXzSXY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLDTWM2OD1yLkCwPEDPxE1? MXPTRW5ITVJ?
LXF-289 M3O3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHmTWM2OD1yLkCwPFE5KM7:TR?= MVzTRW5ITVJ?
RS4-11 NUS2SFR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnlTIprUUN3ME2wMlAxQDN4IN88US=> MU\TRW5ITVJ?
DEL M2HMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPaUHlDUUN3ME2wMlAxQDR3IN88US=> NVTEdGZCW0GQR1XS
OCI-AML2 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELIcFRKSzVyPUCuNFA5PTJizszN NHXoWVNUSU6JRWK=
CCRF-CEM NFmzNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz6UZRKSzVyPUCuNFA5PzFizszN M1GxWXNCVkeHUh?=
A388 M330VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PKTmlEPTB;MD6wNFg4PCEQvF2= Mnq1V2FPT0WU
KNS-42 M{H1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz6OFN5UUN3ME2wMlAxQDlzIN88US=> MXXTRW5ITVJ?
OVCAR-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn4TWM2OD1yLkCwPVA1KM7:TR?= MoK1V2FPT0WU
NCI-H1355 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7SXJhKSzVyPUCuNFA6OTRizszN M3HxfXNCVkeHUh?=
BL-70 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi3N5NKSzVyPUCuNFA6OyEQvF2= NW\CToZPW0GQR1XS
BL-41 NV65Wm9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XsZmlEPTB;MD6wNFk{PCEQvF2= NVrzRlkxW0GQR1XS
A101D NHzuPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vtdGlEPTB;MD6wNFk3KM7:TR?= NFTDdWhUSU6JRWK=
HL-60 NH2yfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEC5OlYh|ryP NXfhd2RmW0GQR1XS
COR-L279 M33iWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEC5PVkh|ryP MmnPV2FPT0WU
NCI-SNU-16 NVTCSFNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEGwNFgh|ryP NE\GU41USU6JRWK=
Calu-6 NYXEdlZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEGwNVIh|ryP MVLTRW5ITVJ?
SR MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjMTWM2OD1yLkCxNFI3KM7:TR?= MUTTRW5ITVJ?
QIMR-WIL NID4PFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEGwN|Mh|ryP NF\iUIZUSU6JRWK=
LB647-SCLC NUjEN3Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSzZ|h5UUN3ME2wMlAyODVzIN88US=> NIDQWJhUSU6JRWK=
RPMI-8226 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHQeZlKSzVyPUCuNFEyODJizszN MlfpV2FPT0WU
SK-PN-DW MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfGfmxZUUN3ME2wMlAyOTF{IN88US=> MkH1V2FPT0WU
SF268 NHPOVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS1TWM2OD1yLkCxNVUyKM7:TR?= NWLyTpBoW0GQR1XS
HD-MY-Z MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLyTWM2OD1yLkCxNVY{KM7:TR?= NUPKSYdsW0GQR1XS
DOHH-2 NX\yeoJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEGyNFMh|ryP M{Drc3NCVkeHUh?=
SCC-3 NYfL[FNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEGyNFQh|ryP MXfTRW5ITVJ?
ST486 NU\tT5VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEGyNFQh|ryP M1S0SXNCVkeHUh?=
NALM-6 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfYepZKSzVyPUCuNFEzOTRizszN MV3TRW5ITVJ?
NCI-H1436 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvnTWM2OD1yLkCxNlMyKM7:TR?= MXzTRW5ITVJ?
KE-37 NWrJOINpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4OzSGlEPTB;MD6wNVI{PCEQvF2= MorzV2FPT0WU
RPMI-8402 NYPvdmVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ISWFKUUN3ME2wMlAyOjV4IN88US=> MVXTRW5ITVJ?
RXF393 M{C0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEGyOVch|ryP NGLQTVJUSU6JRWK=
KARPAS-45 M2TXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjvdIE5UUN3ME2wMlAyOjdizszN NHzIPHBUSU6JRWK=
HOP-62 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXVUGdKSzVyPUCuNFEzPzZizszN MmO1V2FPT0WU
ES1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrYemNKSzVyPUCuNFEzQDhizszN NVvHdoY5W0GQR1XS
L-363 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nTVmlEPTB;MD6wNVM2OSEQvF2= NETEc4lUSU6JRWK=
GI-1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PDXWlEPTB;MD6wNVM4OyEQvF2= MVfTRW5ITVJ?
CTV-1 M2rQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W0XWlEPTB;MD6wNVQ4QCEQvF2= M321d3NCVkeHUh?=
TE-5 NX\TZ2dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln1TWM2OD1yLkCxOFk3KM7:TR?= NGH1V5pUSU6JRWK=
SNU-C2B M1vl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLUN2dKUUN3ME2wMlAyPDl4IN88US=> MXfTRW5ITVJ?
K-562 NFHpcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfRcI9tUUN3ME2wMlAyPTF4IN88US=> NEOwNnpUSU6JRWK=
SNB75 NF;pWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zsVmlEPTB;MD6wNVU1KM7:TR?= NULMVoRoW0GQR1XS
MOLT-13 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjTV4JKSzVyPUCuNFE3OzdizszN MYnTRW5ITVJ?
LS-123 NWrHOlRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTuSYZKSzVyPUCuNFE3PjRizszN M1rT[HNCVkeHUh?=
NCI-SNU-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEG3NFEh|ryP NVz2cGoyW0GQR1XS
Daudi MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEG3NFgh|ryP MVXTRW5ITVJ?
A253 M{TYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfBTWM2OD1yLkCxO|M5KM7:TR?= NVrER21lW0GQR1XS
TGBC1TKB NY\oTGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[5e2lEPTB;MD6wNVc2OiEQvF2= NFLRbpFUSU6JRWK=
SJSA-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjHTWM2OD1yLkCxO|Y4KM7:TR?= MVvTRW5ITVJ?
NCCIT MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XpUWlEPTB;MD6wNVc3QSEQvF2= MnfuV2FPT0WU
NCI-H69 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjkXJVKSzVyPUCuNFE4PzhizszN NGHNOIlUSU6JRWK=
SH-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPFVGpDUUN3ME2wMlAyQDl3IN88US=> MWHTRW5ITVJ?
HCC1187 NW\CXppmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXkOmY3UUN3ME2wMlAyQTJ2IN88US=> NXjTfZZyW0GQR1XS
HCC1599 M4XLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3xT4xrUUN3ME2wMlAzODJizszN MWrTRW5ITVJ?
ONS-76 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132[WlEPTB;MD6wNlA{PiEQvF2= Mn;MV2FPT0WU
KU812 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqzZpJKSzVyPUCuNFIxOzlizszN NX3JNmtwW0GQR1XS
ML-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVPGFHUUN3ME2wMlAzODR5IN88US=> M{HqVXNCVkeHUh?=
HCE-T MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMEKwPVIh|ryP MUDTRW5ITVJ?
NCI-H446 NXnOdJQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXZdFlLUUN3ME2wMlAzOTF{IN88US=> MVTTRW5ITVJ?
RPMI-6666 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEKxOFkh|ryP NFrWSm5USU6JRWK=
MOLT-16 NVLWenk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD1OXhKSzVyPUCuNFIyPTNizszN NWPjSWlWW0GQR1XS
JiyoyeP-2003 M1S3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEKxO|Yh|ryP MX\TRW5ITVJ?
MHH-PREB-1 M4rwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;tdFFKSzVyPUCuNFIyQTFizszN M1nZOnNCVkeHUh?=
MC-CAR MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPYTWM2OD1yLkCyN|I3KM7:TR?= MVfTRW5ITVJ?
BC-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\uW2VKSzVyPUCuNFI{PDRizszN MU\TRW5ITVJ?
KINGS-1 NVzWSlF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\KVYpKSzVyPUCuNFI{PTVizszN NX\DbIVEW0GQR1XS
PF-382 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7RfFRqUUN3ME2wMlAzOzd6IN88US=> M1LVXHNCVkeHUh?=
J-RT3-T3-5 M1XP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzuTWM2OD1yLkCyN|g{KM7:TR?= M3jzRXNCVkeHUh?=
SF539 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hu[mlEPTB;MD6wNlQxOSEQvF2= MWHTRW5ITVJ?
LB831-BLC M13Zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL1NHhKSzVyPUCuNFI1QDVizszN NF3kPZRUSU6JRWK=
DMS-114 NVjNTWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjlOlk1UUN3ME2wMlAzPTB{IN88US=> NF3VRoJUSU6JRWK=
LB1047-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[3PJdKSzVyPUCuNFI2OSEQvF2= NFO5dIpUSU6JRWK=
LB771-HNC M3H1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT0NWNlUUN3ME2wMlAzPTN2IN88US=> MlX4V2FPT0WU
BB65-RCC NF3PeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDyfnRMUUN3ME2wMlAzPTN2IN88US=> M3n0PHNCVkeHUh?=
BV-173 M4TBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEK1OVQh|ryP MWTTRW5ITVJ?
ARH-77 NX3se|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEK2NFEh|ryP M4DSfXNCVkeHUh?=
IST-MEL1 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nUeGlEPTB;MD6wNlYzOyEQvF2= MnXWV2FPT0WU
NB1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEK2PFch|ryP NF3YTVdUSU6JRWK=
EoL-1-cell NXzqOGdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u4cGlEPTB;MD6wNlY5QCEQvF2= NGPaTnpUSU6JRWK=
KY821 NELGfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEK2PVch|ryP MYXTRW5ITVJ?
CMK MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHwcIJKUUN3ME2wMlAzPzN2IN88US=> MVrTRW5ITVJ?
NCI-H2126 M1z2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfBcpRKSzVyPUCuNFI4PjhizszN NH35bpRUSU6JRWK=
NCI-H526 NFi1SIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j5XWlEPTB;MD6wNlg6OSEQvF2= NIKwNmVUSU6JRWK=
COLO-684 NV;oWXFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LqTmlEPTB;MD6wNlkxQCEQvF2= MlnEV2FPT0WU
NCI-H747 NXXzZol2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu3c5NKSzVyPUCuNFI6OzNizszN NHu4e21USU6JRWK=
JAR Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETJXFNKSzVyPUCuNFI6PDZizszN MmPEV2FPT0WU
MEG-01 M1nkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M331dGlEPTB;MD6wNlk4QCEQvF2= MkXmV2FPT0WU
MONO-MAC-6 M1PpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rsRWlEPTB;MD6wN|AzOyEQvF2= NXjyTWJMW0GQR1XS
IST-SL1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEOwOFIh|ryP NWX4RnpTW0GQR1XS
CPC-N MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMEOwO|kh|ryP M4fSfHNCVkeHUh?=
NCI-H1963 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme5TWM2OD1yLkCzNVMyKM7:TR?= NIHQWWhUSU6JRWK=
K052 NHj6NGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XVXWlEPTB;MD6wN|I1PyEQvF2= NWTPSXVVW0GQR1XS
KM-H2 NIfONFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD3TWM2OD1yLkCzN|A4KM7:TR?= NYO3U3V5W0GQR1XS
TE-12 M1G3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEOzNFkh|ryP NF3jdm5USU6JRWK=
TK10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHJPXRrUUN3ME2wMlA{OzV4IN88US=> MWrTRW5ITVJ?
NMC-G1 NVnIPYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi1OHg{UUN3ME2wMlA{PDV{IN88US=> MV7TRW5ITVJ?
no-11 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPncXpKSzVyPUCuNFM1PzhizszN NF;nPHRUSU6JRWK=
NCI-H524 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEO1Nlkh|ryP NULwZ2lPW0GQR1XS
MHH-CALL-2 NWnHUXk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMEO1OlIh|ryP NUnmRVE1W0GQR1XS
GB-1 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEO2JO69VQ>? NWPzT5hbW0GQR1XS
OPM-2 M1GwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEO2O|Mh|ryP NETrTlBUSU6JRWK=
RH-1 M1vxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3iWFdJUUN3ME2wMlA{QDF7IN88US=> M37hdnNCVkeHUh?=
NCI-H64 NGTmToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HpR2lEPTB;MD6wN|g2PyEQvF2= MkPNV2FPT0WU
EVSA-T MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXryWXBKUUN3ME2wMlA{QTJ|IN88US=> MV;TRW5ITVJ?
KARPAS-299 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf3TWM2OD1yLkCzPVgh|ryP NV;GcZd7W0GQR1XS
MZ7-mel NGHzXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHmbXlKSzVyPUCuNFQxPCEQvF2= MXLTRW5ITVJ?
LB373-MEL-D Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4juTWlEPTB;MD6wOFExPSEQvF2= MoP6V2FPT0WU
HEL NYL0N2hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMESxOEDPxE1? M3TnPHNCVkeHUh?=
SW872 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvNNFFKSzVyPUCuNFQzOSEQvF2= MoKxV2FPT0WU
DU-4475 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPiVIFKSzVyPUCuNFQzPDRizszN NWLkNm0yW0GQR1XS
IST-SL2 M2TQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\kZW1VUUN3ME2wMlA1Ojd3IN88US=> NVrSUIN{W0GQR1XS
NCI-H82 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMESzNFch|ryP M1q2ZnNCVkeHUh?=
LC4-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XQTmlEPTB;MD6wOFM2OSEQvF2= NWPSNJBwW0GQR1XS
HDLM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GxcmlEPTB;MD6wOFM6OiEQvF2= MofNV2FPT0WU
MMAC-SF MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr4[otqUUN3ME2wMlA1PTN2IN88US=> NGe0OYZUSU6JRWK=
L-540 NWDYTHlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjuTnFIUUN3ME2wMlA1PjN7IN88US=> NVHUSHYxW0GQR1XS
MZ2-MEL NYjPRXNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMES3OFIh|ryP M2W5SHNCVkeHUh?=
LU-134-A NVf3UpVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzuRVFKSzVyPUCuNFQ4PzNizszN MmnKV2FPT0WU
UACC-257 M33yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrBTWM2OD1yLkC0PFQ6KM7:TR?= NH24PWxUSU6JRWK=
NCI-H1581 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnNXopbUUN3ME2wMlA1QTV|IN88US=> Mn7rV2FPT0WU
NB17 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy4OIV7UUN3ME2wMlA1QTd7IN88US=> MnnNV2FPT0WU
SBC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XWPWlEPTB;MD6wOVA1OiEQvF2= NHOxXHRUSU6JRWK=
TALL-1 M1i2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HsSmlEPTB;MD6wOVA1PSEQvF2= NV7LN3VRW0GQR1XS
NCI-H1304 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[wVGlEPTB;MD6wOVIxQCEQvF2= MUjTRW5ITVJ?
NEC8 M4DLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEWyPFYh|ryP NUH0PVAyW0GQR1XS
CAL-148 M3Gwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqxW|ZKSzVyPUCuNFU1OzlizszN NES4UYNUSU6JRWK=
CGTH-W-1 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEW0OFkh|ryP M1rJ[XNCVkeHUh?=
NCI-H889 NWHXcY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pa[WlEPTB;MD6wOVU6OiEQvF2= NUnCd|R3W0GQR1XS
GR-ST MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPBTWM2OD1yLkC1OlIyKM7:TR?= MX7TRW5ITVJ?
KARPAS-422 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvy[VNKSzVyPUCuNFU3PSEQvF2= Mo\IV2FPT0WU
RPMI-8866 NGrXcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3vdG5KSzVyPUCuNFU4OTJizszN M3\idHNCVkeHUh?=
SCLC-21H NES0[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPhTWM2OD1yLkC1PFg1KM7:TR?= Mm[xV2FPT0WU
COR-L88 M{\sUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrTTWM2OD1yLkC1PVI4KM7:TR?= MUHTRW5ITVJ?
LU-139 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnmb2hKSzVyPUCuNFU6QDZizszN MWXTRW5ITVJ?
SF126 NGTQZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzqTWM2OD1yLkC2NVM{KM7:TR?= Mkm5V2FPT0WU
NCI-H1882 NG\PcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwME[0NlQh|ryP MUTTRW5ITVJ?
EW-24 NGHSW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K3emlEPTB;MD6wOlQ5OyEQvF2= NXTD[GFuW0GQR1XS
CP67-MEL M2Txb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OxfGlEPTB;MD6wOlgyKM7:TR?= NHHTOXFUSU6JRWK=
DG-75 M2DsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXBZpVKSzVyPUCuNFY5QTlizszN MVrTRW5ITVJ?
LOXIMVI MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\1[GlEPTB;MD6wO|AzQCEQvF2= NIrBVIJUSU6JRWK=
HH M1PsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;XTWM2OD1yLkC3NVU4KM7:TR?= NYnGSoVJW0GQR1XS
K5 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEeyNlYh|ryP MUTTRW5ITVJ?
EC-GI-10 NV;NR4RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHlVJAxUUN3ME2wMlA4OjV5IN88US=> MlvQV2FPT0WU
SK-N-DZ MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPTZVhKSzVyPUCuNFc{ODdizszN M3zwfnNCVkeHUh?=
A3-KAW M4fSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfwTWM2OD1yLkC3N|UyKM7:TR?= M2nES3NCVkeHUh?=
MLMA NUX4[pNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XMNmlEPTB;MD6wO|Q3PSEQvF2= NX7QNm9oW0GQR1XS
LB996-RCC MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DBOWlEPTB;MD6wO|cxPyEQvF2= M2\NfHNCVkeHUh?=
OS-RC-2 NVnoc3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEe3OFgh|ryP NVnpbVdLW0GQR1XS
CTB-1 M2j1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\RUWlEPTB;MD6wO|gyKM7:TR?= NUXWU3VnW0GQR1XS
IST-MES1 M3LmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG0UmNKSzVyPUCuNFc6OTJizszN Mk\SV2FPT0WU
LS-1034 M3TofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnlVIlKSzVyPUCuNFgxOzVizszN NUDpOnpkW0GQR1XS
HT MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonITWM2OD1yLkC4NFg3KM7:TR?= NHqxdVVUSU6JRWK=
NCI-H2141 NXj4N3NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEixJO69VQ>? MXnTRW5ITVJ?
LB2518-MEL Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnMTWM2OD1yLkC4NVQyKM7:TR?= MlPTV2FPT0WU
GI-ME-N Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;OfGlEPTB;MD6wPFQ2OiEQvF2= M3v1enNCVkeHUh?=
TGW MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L3VmlEPTB;MD6wPFYxPyEQvF2= MVTTRW5ITVJ?
SK-NEP-1 NH73RlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:2WWdKSzVyPUCuNFg3PDFizszN NYXkR2VGW0GQR1XS
NOMO-1 NEjWVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTISldKSzVyPUCuNFkzPzVizszN NHuxTlVUSU6JRWK=
ES6 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxcnhSUUN3ME2wMlA6PTh7IN88US=> MWnTRW5ITVJ?
NCI-H209 NHzJRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3IdFNKSzVyPUCuNFk4QDZizszN MmLKV2FPT0WU
GAK NXHZTIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMUCxOkDPxE1? M2W2b3NCVkeHUh?=
BC-1 NWH2XoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDLTWM2OD1yLkGwN|YyKM7:TR?= M{L1dXNCVkeHUh?=
KLE M4LNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHqTWM2OD1yLkGwOFQ{KM7:TR?= Mon2V2FPT0WU
EW-3 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDMdIhIUUN3ME2wMlExQThizszN MUHTRW5ITVJ?
NKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn4bWRKSzVyPUCuNVEyKM7:TR?= Mn\TV2FPT0WU
D-336MG M3fZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrLOoppUUN3ME2wMlEyOjR2IN88US=> NF;4copUSU6JRWK=
NB69 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTjTWM2OD1yLkGxN|AyKM7:TR?= NFrzeJdUSU6JRWK=
D-263MG NUnWOXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvNW|NKSzVyPUCuNVE4OTJizszN M17HOnNCVkeHUh?=
KP-N-YS NX;nOFR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUKyPVEh|ryP Mnj2V2FPT0WU
NCI-H1155 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLuTWM2OD1yLkGyOVU5KM7:TR?= MoLJV2FPT0WU
BOKU NH;0WWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUK1O|kh|ryP NXH4fG9rW0GQR1XS
LAMA-84 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUK5PUDPxE1? MofsV2FPT0WU
Raji MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[3S5VKSzVyPUCuNVMyOTdizszN NIi0SmZUSU6JRWK=
LU-65 M2XKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPVPGlJUUN3ME2wMlE{OzB5IN88US=> NHz1UY5USU6JRWK=
NCI-H187 NHK0VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMUO5NlQh|ryP NFu1SohUSU6JRWK=
GCIY MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnriTWM2OD1yLkG0PVAyKM7:TR?= NXzhepBZW0GQR1XS
NCI-H2107 NX70XFVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH2TWM2OD1yLkG1NFgh|ryP NVW2bGN2W0GQR1XS
NCI-H1522 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P6cWlEPTB;MD6xOVI3PiEQvF2= NWnqTHJxW0GQR1XS
NB6 M{e1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfRRmJKSzVyPUCuNVU3OjNizszN Mo\lV2FPT0WU
EM-2 M3nwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzJb49KSzVyPUCuNVU4ODZizszN Ml7QV2FPT0WU
HCC2218 NXzwVmtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r4[WlEPTB;MD6xOVk5KM7:TR?= NV;kZ5I3W0GQR1XS
NCI-H748 NYLhZVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi5cmZKSzVyPUCuNVY{PzZizszN MnLrV2FPT0WU
MS-1 NWXpSFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\4VGlEPTB;MD6xOlU{PyEQvF2= M4XBNHNCVkeHUh?=
NB5 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2qxfGlEPTB;MD6xOlU6PyEQvF2= NVnK[YhSW0GQR1XS
OMC-1 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fZfGlEPTB;MD6xOlY5QCEQvF2= NUPNdIcyW0GQR1XS
NCI-H345 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DjOWlEPTB;MD6xOlkzQCEQvF2= NFPwZmVUSU6JRWK=
L-428 M3jZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i0RWlEPTB;MD6xOlk1PSEQvF2= NIHOPWRUSU6JRWK=
SCH NHn2coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn4TWM2OD1yLkG4Olg2KM7:TR?= M4[xUHNCVkeHUh?=
NCI-H1417 NXix[mJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMUmyNlch|ryP NWLIS2Z3W0GQR1XS
COLO-320-HSR NUP2SJpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\rTWM2OD1yLkG5OVMzKM7:TR?= NIDkbG9USU6JRWK=
BT-474 M3\KSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn5U41KSzVyPUCuNlA5QTJizszN NWrBV2sxW0GQR1XS
GDM-1 NEDuZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ywe2lEPTB;MD6yNVk4OSEQvF2= MlP4V2FPT0WU
NCI-H2196 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TUS2lEPTB;MD6yNlI{PSEQvF2= Mo\2V2FPT0WU
KP-N-RT-BM-1 NXXNO4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXjUWp4UUN3ME2wMlIzOzR7IN88US=> NF2zPYdUSU6JRWK=
KNS-81-FD MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMkK5OVgh|ryP Mlz2V2FPT0WU
COLO-668 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPTOZR1UUN3ME2wMlI{Pjd3IN88US=> MVXTRW5ITVJ?
C2BBe1 NGfVZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13Fb2lEPTB;MD6yOlc1PyEQvF2= NULoOGJnW0GQR1XS
Ramos-2G6-4C10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle3TWM2OD1yLkK2PVU1KM7:TR?= NY\1XpBCW0GQR1XS
CAS-1 M2flcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMkewPVYh|ryP M3vER3NCVkeHUh?=
GOTO MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMke4PVQh|ryP M1vMb3NCVkeHUh?=
LP-1 NFjqelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWydnhzUUN3ME2wMlI5ODV5IN88US=> M1vJOHNCVkeHUh?=
NCI-SNU-1 NIHCdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvBTWM2OD1yLkK5OFIzKM7:TR?= NHjTN3BUSU6JRWK=
EB-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMkm5O|kh|ryP NUm4NZhQW0GQR1XS
MHH-NB-11 NYC2bJN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\DUGRlUUN3ME2wMlMxPDB{IN88US=> MlvBV2FPT0WU
SK-N-FI Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnlTWM2OD1yLkOxOlkzKM7:TR?= MX\TRW5ITVJ?
HCC2157 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjRN5NsUUN3ME2wMlM{QTF|IN88US=> NFToOVhUSU6JRWK=
SIMA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwM{S1PFEh|ryP NX3Oe4xwW0GQR1XS
MDA-MB-134-VI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPad5NZUUN3ME2wMlM3QTJ6IN88US=> Mk\jV2FPT0WU
NCI-H1694 M3LVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1njOmlEPTB;MD6zO{DPxE1? NIfU[4lUSU6JRWK=
EHEB NVHOXoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJWWlEPTB;MD6zPVA5PSEQvF2= NYXibGU6W0GQR1XS
U-266 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwM{m4OFYh|ryP MY\TRW5ITVJ?
LC-1F NWPqV5dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLLTWM2OD1yLkSzO|Y2KM7:TR?= Mmr2V2FPT0WU
SHP-77 NH3UR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH1SIhKSzVyPUCuOFc5PTVizszN NF7SeYNUSU6JRWK=
LS-513 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwNEmzNFch|ryP M2q3[3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID